Patrick A. Plé

1.9k total citations
30 papers, 1.5k citations indexed

About

Patrick A. Plé is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Patrick A. Plé has authored 30 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 14 papers in Organic Chemistry and 8 papers in Oncology. Recurrent topics in Patrick A. Plé's work include PI3K/AKT/mTOR signaling in cancer (9 papers), Biochemical and Molecular Research (7 papers) and Quinazolinone synthesis and applications (7 papers). Patrick A. Plé is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (9 papers), Biochemical and Molecular Research (7 papers) and Quinazolinone synthesis and applications (7 papers). Patrick A. Plé collaborates with scholars based in United Kingdom, France and United States. Patrick A. Plé's co-authors include Laurent Hennequin, Jon Curwen, Christine Lambert‐van der Brempt, Gerard Costello, J M Allen, Tim P. Green, Donald Ogilvie, Stephen R. Wedge, Andrew P. Thomas and Elaine S. E. Stokes and has published in prestigious journals such as Cancer Research, Journal of Medicinal Chemistry and Tetrahedron.

In The Last Decade

Patrick A. Plé

30 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Patrick A. Plé United Kingdom	17	877	572	445	169	124	30	1.5k
John C. Kath United States	19	1.5k 1.7×	905 1.6×	555 1.2×	169 1.0×	61 0.5×	30	2.4k
Octerloney B. McDonald United States	15	937 1.1×	398 0.7×	653 1.5×	265 1.6×	66 0.5×	21	1.7k
Tim P. Green United Kingdom	13	699 0.8×	178 0.3×	504 1.1×	159 0.9×	118 1.0×	14	1.2k
Christine Lambert‐van der Brempt United Kingdom	11	520 0.6×	331 0.6×	243 0.5×	86 0.5×	81 0.7×	20	925
Peter Drueckes Switzerland	15	727 0.8×	173 0.3×	290 0.7×	146 0.9×	118 1.0×	24	1.2k
Amy McMichael New Zealand	8	795 0.9×	770 1.3×	618 1.4×	188 1.1×	69 0.6×	8	1.5k
Elaine S. E. Stokes United Kingdom	17	999 1.1×	367 0.6×	609 1.4×	353 2.1×	60 0.5×	28	1.7k
Ellen M. Dobrusin United States	16	893 1.0×	513 0.9×	608 1.4×	257 1.5×	43 0.3×	24	1.5k
Gary E. Schiltz United States	18	910 1.0×	265 0.5×	306 0.7×	135 0.8×	72 0.6×	52	1.5k
Haile Tecle United States	14	1.1k 1.3×	423 0.7×	403 0.9×	62 0.4×	58 0.5×	27	1.7k

Countries citing papers authored by Patrick A. Plé

Since Specialization

Citations

This map shows the geographic impact of Patrick A. Plé's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick A. Plé with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick A. Plé more than expected).

Fields of papers citing papers by Patrick A. Plé

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick A. Plé. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick A. Plé. The network helps show where Patrick A. Plé may publish in the future.

Co-authorship network of co-authors of Patrick A. Plé

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick A. Plé. A scholar is included among the top collaborators of Patrick A. Plé based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick A. Plé. Patrick A. Plé is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Barlaam, Bernard, Sabina Cosulich, Sébastien L. Degorce, et al.. (2017). Discovery of a series of 8-(1-phenylpyrrolidin-2-yl)-6-carboxamide-2-morpholino-4H-chromen-4-one as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours. Bioorganic & Medicinal Chemistry Letters. 27(9). 1949–1954. 3 indexed citations

Barlaam, Bernard, Sabina Cosulich, Sébastien L. Degorce, et al.. (2016). Discovery of a series of 8-(2,3-dihydro-1,4-benzoxazin-4-ylmethyl)-2-morpholino-4-oxo-chromene-6-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours. Bioorganic & Medicinal Chemistry Letters. 26(9). 2318–2323. 6 indexed citations

Barlaam, Bernard, Sabina Cosulich, Sébastien L. Degorce, et al.. (2014). Discovery of 9-(1-anilinoethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours. Bioorganic & Medicinal Chemistry Letters. 24(16). 3928–3935. 17 indexed citations

Plé, Patrick A., Frédéric Jung, Sue Ashton, et al.. (2012). Discovery of new quinoline ether inhibitors with high affinity and selectivity for PDGFR tyrosine kinases. Bioorganic & Medicinal Chemistry Letters. 22(9). 3050–3055. 7 indexed citations

Plé, Patrick A., Frédéric Jung, Sue Ashton, et al.. (2012). ChemInform Abstract: Discovery of AZD2932 (I), a New Quinazoline Ether Inhibitor with High Affinity for VEGFR‐2 and PDGFR Tyrosine Kinases.. ChemInform. 43(20). 1 indexed citations

Barlaam, Bernard, Richard Ducray, Christine Lambert‐van der Brempt, et al.. (2011). Inhibitors of the tyrosine kinase EphB4. Part 4: Discovery and optimization of a benzylic alcohol series. Bioorganic & Medicinal Chemistry Letters. 21(8). 2207–2211. 26 indexed citations

Plé, Patrick A., Frédéric Jung, Sue Ashton, et al.. (2011). Discovery of AZD2932, a new Quinazoline Ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases. Bioorganic & Medicinal Chemistry Letters. 22(1). 262–266. 44 indexed citations

Green, Tim P., Jon Curwen, Vivien N. Jacobs, et al.. (2009). Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Molecular Oncology. 3(3). 248–261. 176 indexed citations

Hennequin, Laurent, J M Allen, J. Breed, et al.. (2006). N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a Novel, Highly Selective, Orally Available, Dual-Specific c-Src/Abl Kinase Inhibitor. Journal of Medicinal Chemistry. 49(22). 6465–6488. 283 indexed citations

10.

Hennequin, Laurent, Jeffrey C. Allen, Gerard Costello, et al.. (2005). The discovery of AZD0530: a novel, oral, highly selective and dual-specific inhibitor of the Src and Abl family kinases. Cancer Research. 65. 595–595. 16 indexed citations

11.

Barlaam, Bernard, Tim Green, Laurent Hennequin, et al.. (2005). New heterocyclic analogues of 4-(2-chloro-5-methoxyanilino)quinazolines as potent and selective c-Src kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 15(24). 5446–5449. 23 indexed citations

12.

Green, Tim, Laurent Hennequin, Patrick A. Plé, et al.. (2005). Pre-clinical and early clinical activity of the highly selective, orally available, dual Src/Abl kinase inhibitor AZD0530. 65. 1463–1463. 7 indexed citations

13.

Wedge, Stephen R., Jane Kendrew, Jon Curwen, et al.. (2004). The VEGF receptor tyrosine kinase inhibitor AZD2171 inhibits VEGF signaling, angiogenesis, and tumor growth in vivo. Cancer Research. 64. 1052–1052. 7 indexed citations

14.

Plé, Patrick A., Tim P. Green, Laurent Hennequin, et al.. (2004). Discovery of a New Class of Anilinoquinazoline Inhibitors with High Affinity and Specificity for the Tyrosine Kinase Domain of c-Src. Journal of Medicinal Chemistry. 47(4). 871–887. 139 indexed citations

15.

Hennequin, Laurent, Elaine S. E. Stokes, Andrew P. Thomas, et al.. (2002). Novel 4-Anilinoquinazolines with C-7 Basic Side Chains: Design and Structure Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors. Journal of Medicinal Chemistry. 45(6). 1300–1312. 254 indexed citations

16.

Morris, William P., et al.. (1999). A novel series of non-nucleoside inhibitors of inosine 5′-monophosphate dehydrogenase with immunosuppressive activity§§Abbreviations: β, coefficient of interaction; DTH, delayed-type hypersensitivity; FBS, foetal bovine serum; IMP, inosine 5′-monophosphate; IMPDH, IMP dehydrogenase; K′i, apparent inhibition constant for compound I; Kii, inhibition constant for effect on intercept of Lineweaver–Burk plots; K′x, apparent inhibition constant for compound X; MFT, mycophenolate mofetil; MTT, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; MPA, mycophenolic acid; TCA, trichloroacteic acid (10% w/v); v, velocity; v0, uninhibited velocity; and XMP, xanthosine monophosphate.. Biochemical Pharmacology. 58(5). 867–876. 10 indexed citations

17.

Franklin, T. J., Vivien N. Jacobs, Geraint Jones, & Patrick A. Plé. (1997). Human colorectal carcinoma cells in vitro as a means to assess the metabolism of analogs of mycophenolic acid.. PubMed. 25(3). 367–70. 22 indexed citations

18.

Franklin, T. J., et al.. (1996). Glucuronidation associated with intrinsic resistance to mycophenolic acid in human colorectal carcinoma cells.. PubMed. 56(5). 984–7. 49 indexed citations

19.

Franklin, Trevor, et al.. (1995). Glucuronidation by human colorectal adenocarcinoma cells as a mechanism of resistance to mycophenolic acid. Advances in Enzyme Regulation. 35. 91–100. 13 indexed citations

20.

Johnson, Carl R., Patrick A. Plé, & Joseph P. Adams. (1991). Enantioselective syntheses of (+)- and (–)-conduritol C from benzene via microbial oxidation and enzymatic asymmetrization. Journal of the Chemical Society Chemical Communications. 1006–1007. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact